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Abstract
Background: The cytoskeletal adaptor protein vinculin plays a fundamental role in cell contact regulation and affects central
aspects of cell motility, which are essential to both embryonal development and tissue homeostasis. Functional regulation
of this evolutionarily conserved and ubiquitously expressed protein is dominated by a high-affinity, autoinhibitory head-to-
tail interaction that spatially restricts ligand interactions to cell adhesion sites and, furthermore, limits the residency time of
vinculin at these sites. To date, no mutants of the vinculin protein have been characterized in animal models.
Methodology/Principal Findings: Here, we investigate vinculin-DEx20, a splice variant of the protein lacking the 68 amino
acids encoded by exon 20 of the vinculin gene VCL. Vinculin-DEx20 was found to be expressed alongside with wild type
protein in a knock-in mouse model with a deletion of introns 20 and 21 (VCL-DIn20/21 allele) and shows defective head-to-
tail interaction. Homozygous VCL-DIn20/21 embryos die around embryonal day E12.5 showing cranial neural tube defects
and exencephaly. In mouse embryonic fibroblasts and upon ectopic expression, vinculin-DEx20 reveals characteristics of
constitutive head binding activity. Interestingly, the impact of vinculin-DEx20 on cell contact induction and stabilization, a
hallmark of the vinculin head domain, is only moderate, thus allowing invasion and motility of cells in three-dimensional
collagen matrices. Lacking both F-actin interaction sites of the tail, the vinculin-DEx20 variant unveils vinculin’s dynamic
binding to cell adhesions independent of a cytoskeletal association, and thus differs from head-to-tail binding deficient
mutants such as vinculin-T12, in which activated F-actin binding locks the protein variant to cell contact sites.
Conclusions/Significance: Vinculin-DEx20 is an active variant supporting adhesion site stabilization without an enhanced
mechanical coupling. Its presence in a transgenic animal reveals the potential of splice variants in the vinculin gene to alter
vinculin function in vivo. Correct control of vinculin is necessary for embryonic development.
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Introduction
The cytoskeletal adaptor protein vinculin emerged together with
cell adhesion receptors during early metazoan evolution [1]. It is
highly conserved and expressed in all tissues. There is no gene
homologous to the vinculin gene VCL in the genome. VCL gives rise
to one confirmed alternative splice variant, metavinculin, which is
preferentially expressed in muscle tissue [2,3]. The vinculin protein is
found in integrin receptor-based cell contacts, where it contributes to
force transduction from the actin cytoskeleton to the membrane-
apposed cell adhesion complex [4]. The targeting of vinculin to
cadherin-based cell-cell contacts is less well understood, and in this
case an involvement in the mechanical connection of actin filaments
has been questioned [5]. Apart from influencing the mechanical
stability of the cytoskeletal connection, vinculin interacts with
numerous (protein) ligands and appears to fulfil a number of different
functions in cell contacts, affecting regulation of adhesion complex
turnover as well as signal transduction [6,7].
Genetic inactivation (knock-out) of VCL leads to paralysis and
defects in muscle architecture in Caenorhabditis elegans and to
embryonal lethality in mice [8,9]. Heart and brain defects observed
in E8-E10 mouse embryos suggest defective cell migration, and/or
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11530reduced mechanical stability or turnover of contact sites. Develop-
mental heart defects are the most likely cause of embryonal lethality,
although other contributory factors have not been ruled out [9]. Cells
derived from vinculin null animals form adhesion sites and display
increased motility on 2D substrates [9,10]. Consistently, in studies
modulating vinculin expression, cells with high vinculin levels display
reduced cell motility accompanied by low tumourigenicity, while
those with low vinculin have increased motility and high tumour-
igenicity [11,12]. This simple concept, however, has been challenged
by recent reports showing that vinculin-deficient cells are less able to
generate the traction force needed for the invasion of 3D collagen gels
(or tissues) [13,14]. The significance of vinculin function in tissue
organization and mechanical stability of the heart muscle was
demonstrated in heterozygous animals with one vinculin null allele
and through heart-specific vinculin knock-out, which leads to
cardiomyopathies and/or ventricular tachycardia causing sudden
death of young mice [15,16]. The characterization of other essential
function(s) of vinculin requires further animal models.
Studies performed on vinculin null cells and animals indicate that
the protein modulates adhesion and migration of cells and may define
a critical point of regulation in the process of self-assembly and
disassembly of adhesion sites. In fact, the protein’s structure and
biochemical properties suggest the importance of simultaneous
regulation by several interaction partners to restrict high affinity
interactions to adhesion sites [17,18]. The vinculin protein consists of
five alpha-helix bundles (Vd1-Vd5). The globular head (Vd1-Vd4)
and the tail domain (Vd5, Vt) are connected by a flexible proline-rich
linker and can establish an intramolecular,auto-inhibitory interaction
with an estimated Kd of 1nM [17]. In the auto-inhibited
conformation, high-affinity interactions with head ligands such as
talin, alpha-catenin, and alpha-actinin and tail ligands like F-actin
and acidic phospholipids, phosphatidyl-serine or phosphatidyl-
inositol-4,5-bisphosphate (PIP2) are blocked. It has been suggested
that the combinatorial activity of several partners as found only in cell
contacts, is required to unlock the head-to-tail interaction (HTI)
[17,19]. Furthermore, the interaction of HTI-deficient, constitutive
vinculin mutants with talin has been proposed to stabilize talin
activity and to suppress adhesion site turnover. Thus, the critical
impact of vinculin’s intramolecular regulation on the cellular control
of adhesion sites appears to be a consequence of its capacity to sustain
the activation of talin and subsequently of integrin [20].
In this work, we analyse a constitutively active vinculin variant,
vinculin-DEx20, using the knock-in VCL-DIn20/21 mouse model.
Apart from vinculin knock-outs, no other mouse model investigating
vinculin function has been analysed to date. Alternative splicing of
exon 20 removes 2.4 helices from the Vt five-helix bundle domain,
deleting the actin interaction sites as well as essential parts of the head
interaction sites and promotes constitutive ligand binding of the
vinculin head. Homozygous VCL-DIn20/21 animals die between
embryonal day E10.5 to E12.5 with embryos showing exencephaly
andlackofmidlinefusion.Furthermore,theyexpressvinculin-DEx20
in addition to reduced levels of wild type vinculin. The phenotype of
cells expressing vinculin-DEx20 reflects vinculin interactions in
adhesion sites independent of auto-inhibition and cytoskeletal
coupling, and contributes to a better understanding of vinculin
functional regulation in cells and tissues.
Results
Embryonal lethality of the VCL-DIn20/21 mouse is linked
to impaired splicing
To introduce selected mutations at the 39 end of the vinculin
gene, we generated a targeting vector for homologous recombi-
nation, eliminating introns 20 and 21 (Fig. 1A). The knock-in
allele, referred to as VCL-DIn20/21, was designed with the intent
to maintain normal expression of vinculin mRNA and protein,
and subsequently, to allow Cre recombinase-controlled introduc-
tion of mutations in exons 20 to 22 at the C-terminus of vinculin
(suppl. information, Fig. S1). Correct recombination was con-
firmed in targeted 129SV embryonic stem cells and a knock-in
mouse line was established (suppl. information, Fig. S1).
Unexpectedly, during breeding of these knock-in mice no
homozygous (ki/ki) VCL-DIn20/21 animals were born. This
indicated embryonal lethality of the VCL-DIn20/21 mouse. To
analyze at which time point in development homozygous VCL-
DIn20/21-animals die, embryos of different ages were isolated and
genotyped. Indeed, homozygous embryos were detectable up to
E12.5 but not at later stages (Table 1). To check whether lethality
resulted from a lack of vinculin-mRNA transcription from the
VCL-DIn20/21-allele, RT-PCR-analysis was performed on RNA
isolated from E10.5 embryos of the different genotypes. This
analysis using primers in exons 18 and 22 revealed the presence of
the wild type mRNA as well as an additional alternatively spliced
vinculin mRNA lacking exon 20 in both homozygous (ki/ki) and
heterozygous (ki/wt) VCL-DIn20/21 embryos (Fig. 1B). The
identity of this mRNA lacking exon 20 was confirmed by cloning
and sequencing (suppl. information, Fig. S2). As exon 19 is
alternatively spliced and used exclusively in the muscle-specific
variant metavinculin, skipping of exon 20 effectively combines
exons 18 and 21 without altering the reading frame. Analysis of
exon 20 revealed the presence of consensus nucleotide sequences
required for conventional intron splicing (suppl. information, Fig.
S2). Thus, translation of vinculin-DEx20 mRNA results in a
vinculin variant harbouring a defined deletion of 68 amino acids
(encoded by exon 20) equivalent to 8 kDa. The extent of the
deletion in vinculin tail is illustrated in Fig. 1C and D for the gene
and the protein domain fold, respectively. Immunoblot analysis
performed on single embryo protein extracts with a vinculin head
specific antibody (hVin-1, Sigma) confirmed expression of a
vinculin variant of reduced molecular weight in VCL-DIn20/21
(ki/ki) embryos. This protein was coined vinculin-DEx20 (Fig. 1B).
Interestingly, we did not observe additional (proteolytic) protein
bands. Hence in tissue extracts, there was no indication for
enhanced proteolytic sensitivity of the vinculin-DEx20 variant. In
mouse embryonic fibroblasts (MEFs) derived from VCL-DIn20/21
embryos, the half life of the DEx20 form is shorter than that of
wild type vinculin and was estimated at 1.5 days (35 hours) (Fig.
S3). Furthermore, total expression levels of wild type vinculin in
homozygous embryos at embryonal day E10.5 were reduced as
compared to heterozygous and to wild type littermates (Fig. 1B).
Phenotyping of homozygous VCL-DIn20/21 (ki/ki)
embryos
As described above, VCL-DIn20/21 (ki/ki) embryos could be
identified until E12.5 but not at later stages. Furthermore, E12.5
embryos were usually already dead and showed early signs of
resorption. At E10.5 VCL-DIn20/21 (ki/ki) embryos were still
alive and showed the same size as wild type or heterozygous
embryos isolated from the same pregnant mouse, indicating that
embryonic death occurred between E10.5 to E12.5. Morpholog-
ical inspection of VCL-DIn20/21 (ki/ki) embryos revealed a severe
craniofacial defect. The cranial neural folds failed to fuse resulting
in the formation of an exencephaly. Furthermore, other head
structures also failed to fuse at the ventral cranial midline (Fig. 2A9).
Histological investigation of E10.5 embryos confirmed the absence
of ventricles, a phenotype that has also been described for vinculin
knock-out embryos. In addition, the head mesenchyme was loosely
organized and contained massively dilated blood vessels (Fig. 2B9).
Vinculin-DEx20
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heart, liver, spinal cord and gut as well as limb buds, dorsal root
and cranial ganglia showed neither a developmental delay nor any
obvious defect (Fig. 2 B9 and data not shown).
To test whether expression of the vinculin-DEx20 variant affects
cell survival during development, TUNEL-staining on histological
sections from E10.5 embryos was performed. Indeed, whereas
only a few TUNEL positive cells were present in sections from wild
type embryos, a massive increase in TUNEL positive cells could be
detected in VCL-DIn20/21 (ki/ki) embryos. Interestingly, massive
cell death was found almost exclusively in mesenchymal tissue,
ventral to the spinal cord and in the neuroepithelium, but was not
observed in heart or liver (Fig. 2 D9).
Effects of vinculin-DEx20 on cell adhesion sites
To evaluate the potential effects of the vinculin splice variant on
embryonal development, we generated a vinculin-DEx20 expres-
sion plasmid equipped with an N-terminal EGFP for expression
and detection in eukaryotic cells. In C2C12 myoblasts, the
efficiencies of transfection and expression levels of the wild type
and DEx20 forms of GFP-tagged vinculin as determined by FACS
analysis were identical (data not shown). Immunoblots revealed
ratios of 1:1.2–1.8 of endogenous to ectopically expressed protein
and did not show any additional short fragments that would be
indicative of enhanced degradation of the vinculin-DEx20 (data
not shown). Analysis of protein targeting in transfected C2C12
cells revealed strong adhesion site localization concomitant with a
reduced cytoplasmic occurrence of vinculin-DEx20 compared to
vinculin wild type (Fig. 3). Furthermore, contact sites containing
Table 1. Embryonic allele distribution in the VCL-DIn20/21
mouse line.
wt/wt wt/ki ki/ki n
E9 . 5 16% 53% 31% 19
E 10.5 26% 51% 23% 78
E 11.5 32% 43% 25% 44
E 12.5 32% 48% 20% 25
P0 38% 62% 0% 173
Genotype distribution was determined at different developmental stages.
Homo-zygous VCL-DIn20/21 embryos were detectable until embryonal day
E12.5. No homozygous animals were born.
doi:10.1371/journal.pone.0011530.t001
Figure 1. Impaired splicing leads to expression of vinculin-DEx20 in knock-in mice. (A) At the 39end of the vinculin gene VCL, alterations
were introduced for a knock-in approach. An endonuclease restriction site (BamH I) and a lox-P site are inserted into intron 19, 335 bp upstream of
exon 20. The targeting construct continues with a short cDNA for exons 20, 21 and 22 (no introns) and the vinculin 39UTR. (B) RT-PCR performed on
total RNA isolated from E10.5 embryos with primers in exon 18 and 22 detects the expression of an additional shortened vinculin variant from the
knock-in allele. Sequence analysis of the additional band reveals omission of exon 20. Splicing of vinculin exon 18 to exon 21 occurs in-frame and
expression of the shortened protein variant, vinculin-DEx20, from the knock-in allele is detectable by vinculin-immunoblotting. (C) The vinculin tail
consists of a bundle of five amphipathic a-helices (H1-H5) encoded by exons 18, 20, 21 and 22 of the VCL. Use of exon 19 is restricted to the muscle-
specific splice variant metavinculin. Incorrect splicing skipping exon 20 (amino acids G916-Q983) leads to the deletion of vinculin tail helices H2 and
H3 as well as a fragment of helix H4. These regions are involved in interactions of the tail with the vinculin head (green, [17,18]) and F-actin (blue,
[23]), as indicated. The position of mutations in vinculin-T12, a mutant with severely compromised head-to-tail interaction (HTI) [18], is marked (star).
(D) Ribbon model views of the vinculin tail five-helix bundle showing the position of amino acids encoded by exon 20 highlighted in green [22].
doi:10.1371/journal.pone.0011530.g001
Vinculin-DEx20
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central regions of transfected cells.
These alterations of adhesion sites were analysed quantitatively
by determining the average adhesion size and total adhesion areas
in relation to whole cell areas of C2C12 cells, expressing low and
comparable levels of EGFP-tagged wild type or DEx20 vinculin. In
fluorescence images, line profiles confirmed the presence of a
strong cytoplasmic pool of wild type vinculin leading to a
pronounced perinuclear signal, which was absent in cells
expressing vinculin-DEx20 (Fig. 4A). Adhesion site footprints were
extracted from binary transformed fluorescence images (Fig. 4B).
Analyses of footprints from cells expressing either vinculin wild
Figure 2. Homozygous VCL-DIn20/21 embryos are not viable. (A, A9) Lateral view of whole wild type and VCL-DIn20/21 embryos at E10.5. In
the homozygous (ki/ki) VCL-DIn20/21 embryo (A9), exencephaly resulting from a neural tube closure defect is shown (arrow heads). (B, B9)
Haematoxylin-Eosin staining of sagittal sections from wild type and VCL-DIn20/21 embryos at E10.5. m: mesencephalon; t: telencephalon; h: heart; sc:
spinal cord; drg: dorsal root ganglia; cg: cranial ganglia; bv: blood vessels. Corresponding nuclear (C, C9) and TUNEL (D, D9) staining from wild type
and VCL-DIn20/21 embryos at E10.5. Note increased cell death in VCL-DIn20/21 embryos (arrows). Scale bars: 500 mm.
doi:10.1371/journal.pone.0011530.g002
Figure 3. Vinculin-DEx20 expression affects morphology and distribution of adhesion sites. Localization of EGFP-vinculin wild type (A–D)
and EGFP-vinculin-DEx20 (A9–D9) in C2C12 cells. Paxillin staining is employed as an independent marker for integrin-based adhesion sites (C, C9). In
EGFP-vinculin-DEx20 expressing cells, the number and size of central adhesions appear to be increased. Note the reduction of diffuse cytoplasmic
staining (A9). Scale bar: 20 mm.
doi:10.1371/journal.pone.0011530.g003
Vinculin-DEx20
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case) reported a comparable size distribution of adhesion sites with
average adhesion size of 0.6260.03 mm
2 (mean 6 SEM) and
0.6760.03 mm
2, respectively (Fig. 4C). In vinculin-DEx20 ex-
pressing cells, the slight increase in adhesion size (7%) was
accompanied by a reduced whole cell area (17%), decreasing from
an average of 3.060.3610
3 to 2.560.2610
3 mm
2 (mean 6 SEM).
Taken individually, neither characteristic showed statistically
significant differences with p- values (t-test) of 0.32 and 0.09,
respectively. However, analysis of adhesion relative to whole cell
areas confirmed the initial (subjective) impression. The density of
adhesion sites rose from 1661t o2 0 61 sites in 100 mm
2 (mean 6
SEM; p,0.01) and the adhesion area reached 13.260.7% of the
total area of the cell (mean 6 SEM; p,0.001), reflecting an
increase of 40% in vinculin-DEx20 compared to vinculin wild type
expressing cells (Fig. 4C). Hence, quantitative data confirmed
significantly enhanced adhesion following vinculin-DEx20 expres-
sion. This is reminiscent of effects reported for expression of the
vinculin head domain [20] and suggests constitutive binding of
vinculin-DEx20 to talin and other ligands of the vinculin head.
Figure 4. Vinculin-DEx20 effects on the size and density of adhesion sites. (A) Line scans (broken line) taken from fluorescence images
provide intensity profiles (right), which allow comparison of fluorescence signals in adhesion sites and the cytoplasm. Note the strong increase in
basal fluorescence intensity adjacent to the nucleus (shaded) of the vinculin wild type but not the vinculin-DEx20 expressing C2C12 cell. (B)
Processing of fluorescence images (see material and methods) yields whole cell areas and binary footprints of adhesion sites as illustrated. (C)
Footprints taken from C2C12 cells expressing vinculin wild type (n=26) or vinculin-DEx20 (n=28) are used to quantitatively assess number and size
of adhesion sites in relation to the spreading area of cells. Box plots indicate median values and capture 50% of data in boxes and 80% in whiskers.
Mean values, median and statistical significance (t-test) are given underneath. Note the highly significant increase in adhesion density and relative
adhesion area of vinculin-DEx20 expressing C2C12 cell. p-value: **,0.01, ***,0.001.
doi:10.1371/journal.pone.0011530.g004
Vinculin-DEx20
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embryonic fibroblasts
To address the influence of vinculin-DEx20 on vinculin function
in homozygous VCL-DIn20/21 embryos, primary MEFs from
E10.5 embryos were cultured. In these cells, as in the transfection
experiments, immunostaining of endogenously expressed vinculin
revealed distinct localization i.e. low perinuclear intensity and
enlarged adhesion sites in VCL-DIn20/21 (wt/ki) and (ki/ki)
MEFs as compared to VCL (wt/wt) MEFs from littermates,
confirming the impact of vinculin-DEx20 on the cellular control of
adhesion site formation (Fig. 5). Comparable effects were observed
upon expression of vinculin-DEx20 in vinculin knock-out MEFs
and other cell lines (data not shown). To further investigate the
extent of the dominant DEx20 effect, immortalized MEFs of
different genotypes, wild type, VCL null (2/2), and VCL-DIn20/
21 (wt/ki) and (ki/ki), were generated. The migratory behaviour of
the different fibroblast populations was determined, using an
invasion assay that addresses key functional aspects of cell motility
in three-dimensional collagen matrices (collagen gels) [14]. In this
assay, vinculin-deficient cells served as negative control as they
generate low contraction forces [12] and cannot invade collagen
gels mechanically, which is not a consequence of reduced matrix
protease expression or activity [14]. As shown in Figure 6, the
fraction of invasive vinculin null cells was very low with 2.960.5%
(mean 6 SEM), while properties of VCL-DIn20/21 transgenic
cells, (wt/ki) and (ki/ki), were similar with 21.661.8% and
22.262.2% of invading cells, respectively. Remarkably, the
significant reduction in invasive cells (p,0.01) that was observed
with respect to vinculin (wt/wt) MEFs (32.161.7%) did not
correspond to expression levels of vinculin protein (Fig. 6A).
Heterozygous (wt/ki) MEFs expressed more vinculin than wild
type MEFs, whereas (ki/ki) cells expressed 40% of wild type and a
similar amount of DEx20 vinculin. Unlike the embryos (see
Fig. 1B), MEFs in cell culture adjusted their vinculin expression,
and it appears that for cellular invasiveness there is an optimal
expression level of vinculin protein. Moreover, invasion profiles,
which reflect the average depth of invasion (Figure 6B), confirmed
the invasion characteristics of the different genotypes. The average
depth of invasion was 76.062.2 mm (mean 6 SEM) for (wt/wt)
MEFs, 39.862.9 mm and 54.963.1 mm for transgenic (wt/ki) and
(ki/ki) MEFs, respectively, and 11.961.0 mm for vinculin null (2/
2) MEFs. In contrast to other constitutive mutants like vinculin-
LD that block migration at low expression rates [21], there is no
indication for a dominant negative effect of vinculin-DEx20
expression on cell migration in the three-dimensional matrix
environment.
Ligand binding of vinculin-DEx20
Having characterized vinculin-DEx20 as a constitutive variant that
can enhance adhesion site occurrence, mostlikely as aconsequence of
a reduced head-to-tail interaction, we next addressed the impact of
ligand binding to the vinculin-DEx20 tail domain. Humphries et al.
suggested selective targeting of the vinculin tail (Vt) to a subset of actin
filaments [20]. The molecular details of such interaction, however,
have not been resolved. In C2C12 cells, expression of EGFP-tagged
Vt (amino acids 879–1066) carrying the F-actin and lipid binding
site(s) of the protein [22,23], revealed adhesion site localization and
some decoration of actin stress fibres by wild type vinculin tail
(Fig. 7A–D). The positions of adhesion sites were marked by paxillin
staining. When vinculin tail-DEx20 was expressed, EGFP-staining
was much more diffuse, indicating reduced (lateral) binding to actin
filaments (Fig. 7A9–D9). Line profiles of transfected cells confirmed
the correlation of the EGFP-Vt wild type with actin filaments and
paxillin signals, while no such correlation was evident for the EGFP-
Vt-DEx20 signal, indicating disruption of targeting (Fig. 7E, E9).
A strong influence of the vinculin-DEx20 tail domain on the
cellular function of vinculin became evident when we investigated
residency times of different EGFP-tagged variants by fluorescence
Figure 5. Distribution of endogenous vinculin in VCL-DIn20/21 MEFs. Vinculin localization (A-A0; immunostaining) and actin filaments (B-B0;
phalloidin staining) are depicted in mouse embryonic fibroblasts (MEFs) derived from E10.5 embryos. Cells from VCL-DIn20/21 littermates of all
genotypes, (wt/wt) (A–C), (wt/ki) (A9–C9), or (ki/ki) (A0–C0) are analyzed. In vinculin-DEx20 expressing MEFs, central adhesions appear pronounced and
the cytoplasmic staining is reduced. Heterozygous (wt/ki) MEFs display an intermediate phenotype. Scale bar: 20 mm.
doi:10.1371/journal.pone.0011530.g005
Vinculin-DEx20
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comparison of vinculin kinetics, since we have previously obtained
highly reproducible values in these cells with a number of different
proteins and domain constructs [24]. Bi-exponential fit of fluores-
cence recovery curves indicated two kinetic pools of protein in
adhesion sites with t1/2(I) corresponding to tethered protein and t1/
2(II) reflecting the pool of actively bound protein[24]. Figure 8 reveals
that the half life time t1/2(II) of 1661 s (mean 6 S.D.) for wild type
vinculin is relatively low in C2C12 cells as compared to other cells,
but well within the range of values reported for vinculin in the
literature [21,25,26]. Consistent with results obtained in NIH3T3
cells [20], vinculin head domain constructs showed 2–3 times
prolonged residency times in C2C12 cells, with t1/2(II) of 3962sa n d
4963 s for vinculin head Vd1-Vd3 (amino acids 1–716) and vinculin
head Vd1-Vd4+ (amino acids 1–880, profile not shown), respectively.
Thus, the half life time t1/2(II) of 12067 s determined for vinculin-
DEx20, which is 7 times longer than that of vinculin wild type,
demonstrated strongly enhanced binding of this vinculin splice
variant to adhesion sites. This behaviour differed from that of (pure)
vinculin head interactions. Most notably, the vastly prolonged
residency time was not accompanied by a decrease of vinculin-
DEx20 protein in the mobile fraction (74%). In contrast, vinculin-
T12, an established head-to-tail binding mutant with defective Vd4-
Vt(Vd5) interaction yet intact F-actin binding [18], showed a sharp
reduction in its mobile fraction to 33% and t1/2(II) of 315632 s in
C2C12 cells (Fig. 8). These differences in protein behaviour
presumably reflect enhanced ligand interaction of the intact tail
domain in vinculin-T12, compared to that of vinculin-DEx20, which
lacks the 68 amino acids of exon 20.
Discussion
Here we report biochemical and functional consequences of the
genetic removal of introns 20 and 21 from the vinculin gene VCL.
Homozygous (ki/ki) embryos carrying the VCL-DIn20/21 allele,
die between E10.5 to E12.5 and display severe craniofacial defects.
Vinculin expression analysis in E10.5 embryos reveals reduced
levels of the endogenous wild type protein and the appearance of
an alternatively spliced vinculin variant lacking exon 20. Vinculin-
DEx20 is a (calculated) 109 kDa protein devoid of the actin
interaction sites of the tail (Vd5) and of the inhibitory
intramolecular head-to-tail interaction (HTI) (Vd4–Vd5). Re-
Figure 6. VCL-DIn20/21 (ki/ki) MEFs invade collagen gels. (A) Fibroblasts of different genotype were seeded onto three-dimensional collagen
matrices (gels) and cultured for 3 days. In vinculin-deficient VCL (2/2) MEFs, the low percentage of invasive cells confirms strong inhibition of cell
adhesion/invasion, as reported earlier [14], whereas transgenic MEFs, VCL-DIn20/21 (wt/ki) and (ki/ki), are reduced with respect to (wt/wt) controls.
Variance analysis established significant differences between all genotypes except for (wt/ki) and (ki/ki) (post hoc Holm-Sidak, p,0.01). The
immunoblot (IB) reveals vinculin protein levels, and numbers underneath indicate the average expression compared to (wt/wt) MEFs (n=3). Note
that vinculin expression levels of the different fibroblast genotypes do not show a linear correlation to invasiveness of cells. (B) Invasion profiles
expressed as cumulative probability of finding a cell at or below a given invasion depth reveal that (wt/ki) and (ki/ki) MEFs invade with similar
efficiency, and (wt/wt) MEFs invade deeper. Invasion of VCL (2/2) MEFs is almost entirely inhibited. Error bars: SEM.
doi:10.1371/journal.pone.0011530.g006
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residency times of the protein and stabilization of adhesion sites,
affecting cellular control of adhesion and motility.
The VCL-DIn20/21 mouse and consequences of VCL
targeting
T h ep h e n o t y p eo ft h eV C L - DIn20/21 mouse only partially
resembles the phenotype of vinculin knock-out animals, although
both mouse mutants die during midgestation after having completed
gastrulation. Both mouse mutants exhibit a cranial neural tube
closure defect resulting in an exencephaly. As suggested by Xu et al.
[9], this phenotype might be due to a defect in the regulation of the
actin cytoskeleton, which is crucial for bending of the neural folds
toward the midline. The strongly dilated blood vessels in the head
most likely result from a failure in brain formation, as the head
mesenchyme has more space and is therefore only loosely associated
and less able to counteract the blood pressure.
Despite these similarities, the phenotype of the vinculin null
embryos is more severe than that of the VCL-DIn20/21 embryos.
Vinculin null embryos are already smaller at E8.5 and only some
survive until E10.5 [9]. In addition, in vinculin null embryos the
cranial nerves failed to form and the dorsal root ganglia were much
smaller. Beside the neuronal defects, vinculin knock-out embryos
show a severe malformation of the heart, which never initiated
contraction [9]. The heart defect prevents normal nutrient supply
and removal of waste products in the fast growing embryo and, thus,
is the most likely cause of early death and dramatic developmental
retardation in the knock-out embryos.
In contrast, VCL-DIn20/21 embryos show no growth retardation
and are the same size as wild type embryos at E10.5. Consistently,
histological analysis of hearts from VCL-DIn20/21 embryos revealed
normal differentiation into epicardial, myocardial and endocardial
structures. In addition, there was no obvious defect in the formation
of the peripheral nervous system in these embryos. Thus, reduced
levels (far below 50%) of wild type vinculin are probably sufficient to
sustain normal organ development. Despite this absence of apparent
phenotype, expression of vinculin-DEx20 protein and reduced
expression of wild type vinculin cause apoptotic cell death in the
neuralepitheliumand in mesenchymal cellsventralto the spinalcord.
Whether or not this is a consequence of defective cell adhesion and
migration remains unclear.
Studies on mice carrying vinculin null (knock-out) alleles
provide evidence that one functional vinculin allele is sufficient
to allow regular embryonal development. Heterozygous mice are
fertile and display no obvious pathology. Investigating cardiac
function in adult heterozygous vinculin null mice, Ross and co-
workers report stress-inducible cardiac complications [15]. In
these animals, vinculin protein levels in the heart are decreased by
about 60%. Consistent with morphological observations in knock-
out embryos [9], these findings suggest that a critical threshold
concentration of vinculin is required to preserve functional
integrity of at least some tissues. In adult heterozygous VCL-
Figure 7. Actin filament binding of vinculin tail (Vt)- DEx20 is defective. Co-localization studies of EGFP-tagged vinculin tail (aa 879–1066)
and F-actin in C2C12 cells show stress fibre decoration and adhesion site localization for the wild type tail (A–D) and a predominantly diffuse
distribution of vinculin tail-DEx20 (A9–D9) confirming differences in actin filament interaction. Enlargements (2,3x) refer to boxed areas in (D) and (D9),
respectively. Paxillin staining marks adhesion sites (C, C9). Scale bar: 20 mm (8.6 mm enlargement). (E, E9) Line profiles taken from all three protein
channels (A–C/A9–C9; broken lines) reveal correlation of EGFP-Vt (E), but not of EGFP-Vt-DEx20 (E9), with F-actin and paxillin intensity distributions.
Selected adhesion sites (open squares) and actin stress fibres (open triangles) are marked.
doi:10.1371/journal.pone.0011530.g007
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reduction of vinculin levels to 40–60% in otherwise normal
animals (S. Marg, W. H. Ziegler, unpublished data). Since the
minimum levels of vinculin allowing normal embryonal develop-
ment have not been established and would require a mouse model
with tuneable vinculin expression, we cannot fully exclude that
lethality of homozygous VCL-DIn20/21 embryos is due at least in
part to insufficient vinculin levels.
Characteristics of the vinculin-DEx20 protein
Vinculin-DEx20 is detected as one protein without additional
head fragments in immunoblots of primary MEF cells derived
from VCL-DIn20/21 (ki/ki) mice and upon ectopic expression in
different cell lines. In cells, this protein displays preferential
adhesion site targeting together with a low cytoplasmic pool and
induces a rise in adhesion site density. These characteristics
indicate constitutive binding of vinculin-DEx20 to head ligands
such as talin and alpha-actinin. Direct comparison of the DEx20-
splice variant to vinculin head constructs or the head-to-tail
binding mutant vinculin-T12 reveals informative differences.
Ballestrem and co-workers report that a range of vinculin head
constructs as well as vinculin-T12 can induce a 3–4 fold increase in
total adhesion area covering more than 20% of the cell’s spreading
area. This drastic rise appears to result from a 2-fold increase in
average adhesion size and a 2–3 fold rise in the number of
adhesions [20]. In comparison, vinculin-DEx20 causes only
moderate changes in number and size of adhesions leading to
13% of relative adhesion area or a 1.4 fold increase with respect to
vinculin wild type expression. Differences in residency times,
which strongly depend on the regulation of vinculin head
interactions [25], are even more striking. In C2C12 cells, half
life times of head domain constructs, Vd1–Vd3 and Vd1–Vd4+,
are similar to the values reported for NIH3T3 cells [20]. In
contrast, the half life of vinculin-DEx20 was 2.5–3 times longer
than that of these head constructs, and vinculin-T12, which was
more difficult to investigate due to low recovery, revealed 6.5–8
fold longer residency times. In conclusion, vinculin-DEx20 displays
strong head binding accompanied by a moderate induction of cell
contacts and no dominant negative effect on cell motility/
migration.
Some studies indicate that half life times of vinculin (and
vinculin head) in adhesions are directly linked to those of talin and
Figure 8. Residency times of constitutively active vinculin variants in focal adhesions. Fluorescence recovery after photobleaching (FRAP)
experiments using EGFP-tagged vinculin constructs were used to determine half life times of bound protein t1/2(II) (means 6 S.D.) and the percentage
of protein in the immobile fraction (IF) [24]. (I, II and IF refer to fractions of tethered, bound and immobile protein in adhesions, respectively; see
Results). Comparison of vinculin wild type (red) with a vinculin head construct, Vd1–Vd3 (blue), the vinculin-DEx20 variant (green), and the HTI
mutant vinculin-T12 [18] (orange) reveals significantly increased half lives of the different constructs in adhesion sites. Residency times t1/2(II) of the
(constitutive) head construct, vinculin-DEx20, and vinculin-T12 were 2, 7 and 20 fold as long, respectively. The T12-mutant showed no tethered
fraction (I). Thus, mono-exponential regression was calculated (t1/2(II) only). Note different time scales used on the x-axes. Vinculin head constructs
and vinculin-DEx20 show comparable immobile fractions (IF), whereas the recovery of vinculin-T12 is very low. Reduced amounts of tethered protein
(I) in the mobility distribution plot, as compared to wild type, indicate constitutive ligand binding. Error bars: S. D.
doi:10.1371/journal.pone.0011530.g008
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[27] and consequently talin-induced integrin activation [20,25],
while other proteins of the cell adhesion complex such as paxillin
remain unaffected. Hence we can assume that (i) the expression of
vinculin-DEx20 will enhance talin and integrin activation, leading
to enhanced number and stability of adhesion sites, and that (ii)
this effect is responsible for the functional consequences of exon 20
removal. Deletion of this exon from the vinculin tail five-helix
bundle (see Fig. 1C, D) removes helices H2, H3 and a fragment of
H4 including the two characterized interaction sites for actin [23],
the interaction sites with domains Vd4 and Vd1 (partial) of
vinculin head [17,18] and the basic ladder of helix H3. Thus,
vinculin tail-DEx20 lacks the characterized interaction sites for
actin filaments and, similar to vinculin-T12, shows a strongly
reduced autoinhibitory head-to-tail interaction. These changes can
account both for the constitutive talin binding of the head domain
in vinculin-DEx20 and for the poor or absent F-actin interaction of
the tail domain.
Consequences for the interaction of vinculin tail-DEx20 with
acidic phospholipids are less obvious. This interaction is
functionally important for vinculin’s activity and residency time
in adhesions and competes for actin filament binding [6,28].
Consistently, in cells expressing vinculin-LD, a mutant lacking the
interaction with acidic phospholipids, spreading and motility
defects were observed, which were linked to suppression of lipid-
mediated adhesion site dissolution [21]. Structural data and
mutagenesis indicate that several parts of the tail are involved in
lipid interactions, the basic ladder (H3), the basic collar and the
hydrophobic hairpin at the C-terminus [21,26,29]. In vinculin-
DEx20, the basic ladder and a part of the basic collar but not the
C-terminus are missing, suggesting impaired interaction of
vinculin-DEx20 with acidic phospholipids. However, a recent
study using C-terminal tail peptides stresses hydrophobic aspects of
the membrane interaction [30] and the biophysical characteriza-
tion of vinculin mutants in cells highlights the impact of the C-
terminal peptide on lipid anchoring and traction formation [31].
Therefore, the C-terminus of vinculin-DEx20 should support
membrane association and sustain vinculin’s influence on
mechanical properties of the plasma membrane. Since residency
times observed for vinculin-DEx20 in adhesions are long
compared to vinculin head constructs, it seems likely that adhesion
site dynamics and function of the DEx20-splice variant are
controlled by a combination of vinculin head and vinculin tail-
lipid interactions.
Finally, the altered lipid binding site based on the basic collar
and hydrophobic hairpin of vinculin tail may still be subject to
regulation by protein phosphorylation. In the DEx20-tail, Y1065
may be phosphorylated via the FAK-src signalling axis, which is
associated with enhanced adhesion turnover [32], and this might
down regulate electrostatic interactions of the basic collar with the
negatively charged membrane. Furthermore, FAK-mediated
strengthening of adhesion sites requires talin and negatively affects
steady-state levels of vinculin incorporation [33]. Thus, vinculin-
DEx20 is expected to uncouple the activation of talin and integrins
from the mechanical connection to the cytoskeleton, while
maintaining responsiveness of vinculin for intracellular signalling
via acidic phospholipids and phosphorylation. This regulation
would account for the moderate effects on the cellular control of
adhesion sites and migration observed upon expression of vinculin-
DEx20.
Tissue functions of vinculin
Vinculin is a phylogenetically conserved single-copy protein
which, apart from providing unique functions during embryonal
development, is essential in adult heart tissue, where it is required
for long-term preservation of cardiac function [9,15,16], so that
mutant forms have been associated in a number of studies with the
occurrence of cardiomyopathies in man [34–36]. For all other
tissues, elucidation of critical vinculin involvement still awaits
experimental validation by selective knock-out or knock-down
approaches. Detection of the splice variant vinculin-DEx20, which
gives rise to a protein with vinculin-related, unique biochemical
properties, opens up the prospect of identifying novel vinculin
variants with modified function, which may be associated with
pathological conditions.
In conclusion, we here present the detailed characterization of a
new variant of the cell adhesion protein vinculin in vitro and in
mice in vivo. The mutant protein lacks sites involved in functionally
important interactions with actin as well as with its own head
domain turning the mutant insensitive to normal regulatory
interactions. The constitutively active behavior of the protein is
associated with severe malformations during embryonic develop-
ment in mice providing in vivo evidence for the functional
importance of a fine tuned regulation of vinculin function.
Materials and Methods
Ethics statement
Mouse breeding and experiments were performed in the animal
facilities of the Faculty of Medicine, University of Leipzig
according to European (Council Directive 86/609/EEC) and
German (Tierschutzgesetz) guidelines for the welfare of experi-
mental animals and were approved by the local authorities
(Landesdirection Leipzig). Mice were housed in a 12 h/12 h light
dark cycle with access to food and water ad libitum.
Analysis of mouse embryos
Preparation of staged embryos and genotyping. Hetero-
zygous animals were mated and 12–16 hours later females were
examined for the presence of a vaginal ejaculatory plug. The day of
plug detection was determined as E0.5 of pregnancy. Embryos were
isolated at indicated time points. DNA retrieved from the amnions
was used for genotyping PCR with primers 59AGTGAAGACGC-
CTGTATGG and 59AGCAGCCCTCTGGAAGGAC. PCR
performed for 33 cycles with an annealing temperature of 60uC
and 30 s of elongation time resulted in a 271 bp fragment for the wild
type and a 324 bp fragment for the transgenic allele comprising the
lox-P site.
RT-PCR analysis of RNA splicing. Embryos were lysed and
RNA was isolated with the RNeasy mini kit (Qiagen) using on-
column DNAse digestion. RT reaction was performed with the
Revert Aid First strand c-DNA synthesis kit (MBI Fermentas) and
the specific primer 59 GGGAGTCTTTCTGACCCAG 39 (exon
22). PCR was performed with recombinant Taq-DNA polymerase
(MBI Fermentas) using the forward primer 59 GAT-
GAGCTGGCTCCTCCTAAG 39 (exon 18), and the reverse
primer used for c-DNA synthesis. PCR performed for 39 cycles
with an annealing temperature of 60uC and 60 s of elongation
time, resulted in 620 bp and 420 bp fragments for wild type and
DEx20 vinculin mRNA, respectively. The identity of the DEx20
mRNA was determined by direct sequencing.
Immunoblotting. Embryos were homogenized in lysis buffer
(50 mM Tris pH 7.5, 300 mM NaCl, 5 mM EDTA, 1% (w/v)
Triton-X-100, 1% (v/v) Protease inhibitor cocktail (Sigma)) and
incubated for 30 min on ice. Debris was removed by
centrifugation, 13000 rpm at 4uC. Protein concentration in
supernatants was determined using the BCA assay (Pierce).
Supernatants were diluted with 2x SDS-loading buffer (Sigma)
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each embryo were loaded onto 8% SDS-polyacrylamide gels and
separated. After transfer onto nitrocellulose membrane,
immunodetection was performed using the vinculin antibody
hVin-1 (Sigma) as described below.
Embryo embedding and staining. Embryos were fixed
using 4% PFA in phosphate buffer over night at 4uC. Thereafter,
embryos were washed 3 times in PBS/20 mM glycine, stepwise
dehydrated in ethanol and finally embedded in paraffin. 5 mm-
sections were taken and mounted onto glass slides. Paraffin
sections were stained with haematoxylin and eosin. TUNEL
staining was performed according to the manufacturer’s protocol
(Roche) and counterstained with DAPI (Invitrogen).
VCL-DIn20/21 (ki/ki) mouse embryonic fibroblasts
(MEFs). To isolate MEF cells from E10.5 embryos, brain and
dark red organs were removed. Thereafter, embryos were washed
in sterile PBS and cut into smaller pieces. Cells were separated by
0.05% trypsin treatment for 5 min at 37uC. The digest was
stopped with FCS and dispersion of cells was enhanced by up and
down pipetting through a 1 ml tip. MEFs were seeded onto cell
culture dishes and cultured in DMEM (high glucose), 10% FCS,
2 mM L-glutamine and antibiotic/antimycotic mix (GIBCO). Cell
preparations from each genotype (passages 2 or 3) were
immortalized by retroviral transduction of SV40 LT antigen.
Immortalized populations were tested for vinculin expression
levels. Their migratory capacity was determined in three-
dimensional collagen invasion.
Plasmid constructs. Vinculin expression constructs were
based on the vinculin full-length clone in pEGFP-C2 (Invitrogen)
and the vinculin tail construct (Vt 879–1066) as described earlier
[21]. Vinculin exon 20-deletion (DEx20) constructs were generated
using the QuikChangeH site-directed mutagenesis kit (Stratagene),
sequenced and subcloned.
Treatment and analysis of cells
Cycloheximide treatment and protein quantification. To
assess stability of vinculin transcripts, MEFs were treated with
10 mM cycloheximide, which blocks protein synthesis [37]. Survival
of cells was established in a pilot experiment using LDH release as
viability marker [38]. For the assay, MEFs were seeded onto 6-well
plates (Greiner) and treated the following day with cycloheximide
for up to 30 hours. After the treatment, cells were trypsinized,
counted and lysed in 2x-SDS sample buffer. Extracts of 60,000 cells
were loaded per lane and immunoblotted, using primary antisera
for vinculin, hVin-1 (1:10,000; Sigma), alpha-tubulin (1:5,000;
Sigma), or c-myc (1:1,000; Millipore) as well as HRP-conjugated
secondary serum (1:10,000; Dianova). Protein extracts for the
determination of protein expression in MEFs and transfected
C2C12 cells were handled accordingly.GFP-tagged constructs were
detected using rabbit anti-GFP (1:1,000; Invitrogen).
Protein bands were visualized using ECL (GE Healthcare)
according to manufacturer’s protocol and Amersham Hyperfilm
ECL (GE Healthcare). Films were scanned at 600 dpi/16bit
greyscale (Epson 2480) and band intensities determined using
background subtraction and gel analysis from ImageJ software
(National Institutes of Health, http://rsb.info.nih.gov/ij, version
1.42). Graph plots and statistical analysis were carried out using
Excel 2004 for Mac (Microsoft).
Transfection and immunostaining of MEFs and C2C12
cells. MEFs were seeded onto glass coverslips and transfected
(where indicated) on the following day with vinculin expression
constructs (0.5 mg DNA) using FugeneHD (Roche) according to
manufacturer’s protocol. After 24 h of transfection, cells were
fixed in phosphate-buffered 4% paraformaldehyd for 10 min at
37uC. Coverslips were washed with PBS/20 mM glycine,
permeabilized in PBS/0,01% Tween 20 for 5 min and blocked
for 15 min in blocking solution (1% BSA, 5% FCS, 0.05% Triton-
X-100). After 1 hour of incubation with the vinculin-specific
antibody hVin-1 (Sigma, 1:800–1,000 in blocking solution), cells
were washed in PBS and incubated for 30 min with (i) goat-anti-
mouse-alexa-488 conjugated secondary antibody (1:800–1,000),
(ii) DAPI (1:250) and (iii) alexa-568-conjugated phalloidin (1:100)
in blocking solution (all three Invitrogen). Coverslips were washed
in PBS (36) and water (16) and mounted using Mowiol (Hoechst).
Fluorescence images were taken with a Zeiss Axiovert 200
microscope with HXP 120 illumination using AxioVision 4,7
software (Zeiss).
C2C12 myoblasts [24] were cultured in Dulbecco’s modified
Eagle’s medium (PAA), 10% fetal calf serum (Gibco) and 2 mM L-
glutamine (PAA). Subconfluent cells were split and seeded onto
fibronectin (30 mg/ml) coated glass coverslips. On the following
day, myoblast cells were transfected with vinculin expression
constructs using Nanofectin transfection reagent (PAA) according
to the manufacturer’s instructions and subsequently handled as
detailed for MEFs (see above).
Adhesion site analysis. Localization and quantification of
adhesion parameters, such as "whole cell area", "adhesion
number" and "adhesion size" was achieved by processing the
fluorescence images of GFP-tagged vinculin variants with ImageJ
software. 16bit TIF-images were treated with a cell edge-detection
procedure to determine the whole cell area and to limit adhesion
quantification to this area. The order of commands for the cell
edge-detection was: enhance contrast, FJ edges, make binary,
dilate, close, fill holes, and erode. In a second step, the (same)
original image was used to select vinculin containing adhesions
and to produce the adhesion pattern or footprint. The following
commands were used: subtract background, enhance contrast, set
threshold, convert to mask. By thresholding, images were reduced
to vinculin-containing adhesion patters. "Analyze particles"
provided number and size of adhesions from the binary
footprint. Graph plots and statistical analysis, normality test and
two-tailed unpaired t-test, were carried out using Sigma Plot 10
(Systat).
Three-dimensional collagen invasion assay. Preparation
of gels and cell invasion analysis were performed as described
previously [14]. 100,000 cells were seeded on top of the collagen
matrix (2.4 mg/ml) and cultured for 72 hours. At this time period,
differences in the invasiveness of cells are clearly visible. After
fixation (2.5% glutaraldehyde in PBS), the number of invaded cells
and their invasion depth were determined in 12 randomly selected
fields of view. To determine the percentage of invaded cells, the
adherent cells of the collagen fibre network were also counted.
Invasive properties of immortalized MEFs did not change with
higher passage number. Statistical analysis of variance was carried
out using Sigma Plot 10 (Systat).
Fluorescence Recovery After Photobleaching (FRAP). FRAP
experiments were performed as described earlier [24]. In brief,
transfected C2C12 cells grown on fibronectin-coated coverslips
were observed in an open heating chamber (Warner Instruments,
UK) mounted on an Olympus double scan-headed
FluoView1000 confocal microscope, equipped with a Plan-Apo
1006/N.A. 1.45 oil objective, and controlled by FV10-ASW
software (Olympus). A 488 nm argon laser and 405 nm diode
laser were used for EGFP excitation and bleaching, respectively.
The two scan heads allowed simultaneous bleaching and image
acquisition. The EGFP fluorescence in focal adhesions was
bleached 5 frames after movie start (acquisition speed: 1.1 s per
frame) by a fast circular movement of the 405 nm laser beam
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over time as indicated. For FRAP analysis, only peripheral focal
adhesions of cells expressing medium levels of EGFP-vinculin
constructs and sufficient signal-to-noise ratio were selected. FRAP
movies were analyzed using ImageJ software. Movies showing
clear focus drifts or focal adhesion site growth or dissolution were
discarded. Average fluorescence intensities were determined for
all frames of the movie in three different regions of interest: the
photobleached focal adhesion, background, and the total
fluorescent area of the cell. Measured signals were corrected for
background fluorescence as well as acquisition photobleaching,
and normalized as described [39]. For each recombinant protein,
n.10 recovery curves were determined. Statistical analyses and
graph plots were carried out using Excel 2004 for Mac
(Microsoft) and SigmaPlot 10 (Systat). A bi-exponential
regression function describing an exponential rise to a
maximum was used for the calculation of half-life times of
recovery and protein mobility distributions.
Supporting Information
Figure S1 Establishment of the VCL-DIn20/21 knock-in
mouse line. (A) Genomic structure of the vinculin gene VCL.T h e
knock-in approach for an inducible expression of vinculin-LD, a
lipid binding-deficient mutant of vinculin tail ([26], second half
of the targeting construct), required removal of introns 20 and
21 from the targeting vector. A BamH I endonuclease
restriction and a lox-P site were inserted into intron 19, 335
bp upstream of exon 20. The targeting construct continued with
exons 20, 21 and 22 (no introns) and the 39UTR. Downstream
of the 39UTR (750 bp), a neomycin resistance cassette flanked
by frt-sites, and a second lox-P site were inserted. This sequence
was followed by 335 bp of intron 19, a short exon 20–22 cDNA
mutated in exons 20 and 22 (star) and another vinculin 39UTR.
The targeting vector was transfected into 129SV embryonic
stem cells. (B) Origin of the mouse line VCL-DIn20/21. Homologous
recombination of several ES cell clones was confirmed by
Southern Blot analysis. Two positive clones were injected into
blastocysts. The VCL-DIn20/21 knock-in mouse line was
derived from clone 330 and maintained by intercrossing of
heterozygous animals. A deleter mouse harbouring FLPe [40]
was employed to remove the Neo cassette. 40. Rodriguez CI,
Buchholz F, Galloway J, Sequerra R, Kasper J, et al. (2000)
High-efficiency deleter mice show that FLPe is an alternative to
Cre-loxP. Nat Genet 25: 139–140.
Found at: doi:10.1371/journal.pone.0011530.s001 (0.60 MB TIF)
Figure S2 Alternative splicing of the VCL-DIn20/21 allele. (A)
Sequence analysis of the alternative splice site. RT-PCR using primers in
exons 18 and 22 was employed to obtain a cDNA fragment of
vinculin-DEx20 from E10.5 total RNA. DNA sequencing revealed
mRNA and derived amino acid sequences of the exon 18 to 21
boundary. (B) Pre mRNA of the VCL-DIn20/21 allele. Exon 20
contains consensus nucleotide sequences required for conventional
intron splicing [41]. The proposed branch site ‘CUPuAPy’ (green)
and the splice acceptor site ‘CAG/G’ (underlined) including
pyrimidine-rich region (blue) are indicated. The splice donor site
of exon 18 is maintained (not shown). (Py: C or U; Pu: A or G). 41.
Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P (2002)
Molecular biology of the cell (4th edition), Garland Science, New
York. 319–324p.
Found at: doi:10.1371/journal.pone.0011530.s002 (0.31 MB TIF)
Figure S3 Protein stability of wild type and DEx20 vinculin in
MEFs. (A) Representative immunoblots of vinculin and c-myc. VCL-
DIn20/21 MEFs were treated with 10 mM cycloheximide (CHX)
for the indicated periods of time [37]. Extracts of 60,000 cells
(each) were loaded and immunoblotted. Tubulin signals served as
loading/transfer controls. Note loss of c-myc after 6 hours of
treatment. Wild type vinculin (solid line) remained stable over
30 hours in all MEF genotypes (only (ki/ki) MEFs are shown),
whereas vinculin-DEx20 (broken line) was reduced to 54% (n=4).
(B) Exponential fit of protein levels (broken line; y=0.92 * e
20.02 x
,R
2=0.90) provides an estimate of the vinculin-DEx20 half life
time of 1.5 days (35 hours) in cells. Error bars: S.D.
Found at: doi:10.1371/journal.pone.0011530.s003 (1.05 MB TIF)
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